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disease since 1994. Moreover HAART leads to a profund and sustained
suppression of viral replication with a rise in CD4 + cells count.
Patients and method: We made a cohort study on 32 HIV infected patients:
they made a two years therapy with nucleoside R T inhibitor, nonnucleoside
R T inhibitor and protease inhibitor. We classified the patients according to
the criteria of CDC at the start of therapy: we had 17 (53.12%) patients at
stage A, 6 (18.75%) patients at stage B, 9 (28.12%) at stage C. We considered
the number ofCD4+ cells (Epics-XL-MCL Coulter) and viral load (HIV-l
test version 1.5 ROCHE). We performed the follow-up of the patients at 3-
6-12-18-24 months.
Results and: discussion Seventy-one percent ofpatients at stage A had a viral
load < 400 copies/mL (694 cells/mm3CD4 +, mean value) after 24 months
oftheraPr. 33% ofpatients at stage B had a viral load < 400 copies/mL (328
cells/mm CD4+, mean value). 22% ofpatients at stage Chada viral load <
400 copies/mL (311 cells/mm CD4 + , mean value).
The early initiation ofaggressive combination therapy suppresses the viral
replication and preserve the immune function, as in our cases
P:1/3 - Opportunistic and bacterial infections in HIV
IMoP21! HIV + tuberculosis dual epidemic developernent at
North-West of Russia
A. Vasyliev, Graschenkova, E. Savine
Research Inst. ofPhthysiopulmonology, St.-Petersburg, Russiall Federation
Objectives: To investigate the dynamic of HIV and TB epidemic at the
population of Kalyningrad region.
Methods: Retrospective study was conducted. Cases ofTB and HIV were
analysed for the period 1991-1999.
Results: The firsts two cases of HIV detected before 1991 were analysed by
E. Savine et al. (1992). One of them was imported from Cote d'Ivoire, the
source ofthe other is still unknown Since 1996 is observing the rapid increase
in HIV. At the beginning of 1999 the number of cases has reached 2809
(297.8/100.000). 64.4% of HIV-infected persons were drug users, 2.3%-
children. Sexual transmission was estimated in 13.2%. The incidence ofTB
increases steadily since 1991 (34.7/100.000). By the end of1998 the rate 87.6/
100.000 was reported. The morbidity rate in children waS highest (126.2/
100.(00). In 1996 has begun the registration ofHIV + TB cases: 1996 -10,
1997 - 16, 1998 - 29 patients.
Conclusions: New phase in the development of epidemic of HIV and TB
(dual epidemic) has begun in 1996 at Kalyningrad region. It can be predicted
that in short period there would be dramatic growth in HIV + TB.
Tuberculosis would be most frequent opportunistic infection.
IMoP22! Relationship between HPV and other STD agents In
concomitant cervicitis among HIV posltive women
M. Cupic, A. Knezevic, 0]. Jevtovicl ,]. Ranin l , T. Jovanovic, M. Bujk02
IlIStitute ofMicrobiology and Immunology, School of Medicille, Ulliversityof
Belgrade; I Cetltre for HIV/AIDS, Institute for illfeetiolls alld tropical diseases
"Dr Kosta Todorovic", UKC, Belgrade; 2Institlltefor PIIbUc Health,
Ulliversity ofMotltetlegro, Podgorica, Yugoslavia
Presence ofetiological various genital pathogens on the cervix, represent the
major risk factors for concomitant cervicitis among HIV positive women.
The aim of this study was to investigate the presence of Humatl papilloma
virus (HPV), Chlamydia trachomatis (CT), Mycoplasma homillis (MH), Urea-
plasma urealyticum (UU), Herpes simplex virus (HSV) type 1 and 2 and
Cytomegalovirus (CMV) on the cervix uteri of29 HIV positive women.
The presence ofHPV in cervical smears was diagnosed with HPV-DNA
in situ hybridization test; CT and HSV type 1 and 2 were detected by the test
of direct immunofluorescence; CMV by the test of indirect immunofluor-
escence and genital mycoplasmas (MH, UU) were detected by colorimetric
methode.
The results showed that 9 of29 HIV positive women were HPV positive;
all ofthem had one or more then one STD agent detected in cervical.mca....
Six of9 HIV positive patients had concomitant cervicitis caused by: CT and
HPV (2/9), CT, HSV type 2 and HPV (2/9) and CMV and HPV (2/9). The
other 3 HIV positive women had UU and HPV (1/9). CMV, UU and HPV
(1/9) and CT, UU and HPV (1/9).
HPV associated with other STD agents as cofactors are frequent cause of
concomitant cervicitis among HIV positive women. These agents also have
an important role in the development of cervical dysplasia and cancer, so
their detection will improve the prevention and control of oportunistic
infections among HIV positive women.
lMoP~ A case-control study of herpes zoster following
highly active antiretroviral therapy (HAART)
P. Domingo', O. H. Torres,]. M. Guardiola,]. Ris, M. Gurgui, G.
Vazquez
Hospital de la Sallta Creu i Sant Pall, Barcelona, Spain
Background: Initiation ofhighly active antirerroviral therapy is followed by
unwelcome inflammatory reactions causing distinct clinical syndromes. The
use of these agents may be associated with unforeseen effects not previously
observed.
Methods: Twelve HIV-infected patients with baseline CD4 lymphocyte
counts ofless than 500 cells/ttL were treated because of herpes zoster (HZ)
within 17 weeks starting protease-inhibitor therapy. The control group were
48 HIV-infected patients matched by age, sex, baseline plasma HIV-1 RNA
and CD4 cell count, and length of follow-up. A historical control group
consisting of 12 HIV-infected patients who had HZ before the use of
protease inhibitors was also used for comparison.
Results: Cases of HZ associated with protease-inhibitor therapy were less
severe than historic controls. The incidence of HZ associated to protease-
inhibitor therapy was 8.90 episodes per 100 patient-years. There were
statistically significant differences between patients and controls in the
increase ofthe number ofCD8 cells, both in absolute number and percentage
(p = 0.0004 and p = 0.0001, respectively), while there were no differences
between CD4 counts and plasma HIV-l RNA. In the multivariate analysis
the only clinical circumstance that independently predicted appearance of
HZ was the increase in percentage ofCD8 cells (OR: 1.33; 95% CI: 1.14-
1.54, P = 0.00(2).
Condusions: Initiation ofHIV-I protease-inhibitor therapy in patients with
CD4 cell counts of less than 500 celis/ttL was associated with an increased
incidence ofherpes zoster. No factors predicting a higher risk for developing
clinically evident HZ could be identified in the present study except for a
higher increase in the percentage ofCD8 cells before its appearance.
IMoP24ICryptosporidlosis In HIV infected patients In Western
Poland
G. Baralkiewicz l , A. Majewska2 , P. Sulima2• A. Wemer2,]'Juszczyk
'
, N.
J. Pieniazek
tDept. of Illf Diseases; 2Dept. ofBiology alld Med. Parasitology Univ. ofMed.
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objectives: Evaluation of frequency of the cryptosporidiosis in HIV -
positive patients (pts)
Methods: Forty HIV infected patients (9 F, 31 M, aged x = 34.2 ± 10.2 ys)
were examined for presence of Cryptosporidiosis. Ten of them had
periodically diarrhoeas in history. Risk behaviors in this group were:
homosexual men - 11 pts (27.5%), IVDU - 16 pts (40%), heterosexual -
13 pts (32.5%). Lymphocytes CD4 mean level was 236 ± 188 c/mm3. Stage
ofinfection (CDC 93): category A -20 pts (50%), B - 7 pIS (17.5%), C -13
pts (32.5%). Coinfection with HBV was detected in4 pts (10%), HCV in 17
pIS (42.5%), CMV in 7 pts (17.5%). Probable duration ofHIV infection was
x = 7.5 ± 3.3 ys.
Stool specimens were examined for the detection ofoocysts, coproantigen
(ProSpecT Cryptosporidium Microplate Assay) and DNA od Cryptospor-
idium (PCR).
Results: The presence ofCryptosporidium was detected in 10 patiens (25%).
OOCYSIS, coproantigen and DNA of this parasite was identified soley in one
specimen (F, IVDU, 19 ys), while Cryptosporidium DNA was detected in 8
specimens (6 M: 2 IVDU, 4 homosexual; 2 F: IVDU and heterosexual; aged
29-58 ys, x = 38.4 ± 10.5 ys). Cryptosporidium coproanrigen was found
ouly in one >ample (M, homosexual, 41 ys). There was no difference berween
pts from Crypto (+) and Crypto (-) groups in age, gender, CDC stage,
CD4 count and coinfection with hepatotropic viruses. Crypto (+) pts had
longer duration ofHIV infection than Crypto (-) pIS (p < 0.05). Three of
Crypto (+) pts died within 6 months. Only two Crypto (+) pts had
diarrhoeas which were treated symptomaticly with success.
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Conclusions: Despite of presence of Cryptosporidium in the stools, there was
no any influence on the clinical course of HIV infection in presented group.
IMoP2S[ Declining bacteremia among patients with HIV
infection 95-98
M. L. Pedro-Botet, M. Sabria, N. Sopena, E. Reynaga, X. VaIles,).
Romeu,). M. Modol
Hosp. Germans Trias I Pujol, Badalona, Spain
Objectives: To study the characteristics of bacteremia in HIV patients
attended in a university hospital over a 4 year period (1995-1998).
Methods: All the significant bacteremias observed in HIV positive patients
reponed by the Department of Microbiology from January 1995 to
December 1998 were included. Microbiological data were stratified in to
two periods (I: 1995-1996 and II: 1997-1998).
Results: A total of 187 bacteremic episodes were observed in 175 HIV
patients. The number and incidence of bacteremies (nO bacteremies/l000
patients/year) stratified by period I and II are reponed in the table:
Period I (1995-1996) Period" (1997-1998)
Variable 419/1980 (21.16%) 251/2344 (10.71%) p O.()()()()OO
CD4 < 50* nU 11u p
Gram-positive 51 14.16 .'l4 9.44 0.07
Gram-negative 43 11.94 20 5.55 0.005
Pseudomona spp. t.'l 3.61 3 0.83 0.02
M. tuberculosis 17 4.72 5 1.38 O.oJS
Atypical
Myeobaeteria 29 8.05 4 1.11 0.00002
MAl 21 5.88 3 0.83 0.0004
Global 154 42.75 72 20 0.OOOOOOOO
•patients with a CD4 count SO/patients tested for CD4 during the pcriod evaluated
Conclusions: 1. The total number of bacteremia episodes has decreased
significandy from 1995 to 1998 according to the improvement of CD4
counts and the introduction of new antiretroviral therapy. 2. The most
significant decrease was observed in Pseudomonas spp, Mycobacterium
tuberculosis and MAl. Streptococcus pneumoniae was the most prevalent
microorganism causing bacteremia during 1997-1998.
IMoP26!lnfections due to Streptococcus pneumoniae in
dinical isolates from HIV infected patients
S. Erscoiu, S. Florescu, C. Chirculescu, C. Patru, O. Dorobat, D. !spas, E.
Ceausu, P. Calistru, L. Paun
Clinic of Infectious and Tropical Diseases Dr. V. Babes, Bucharest, Romania
Objectives: To evaluate the incidence of penicillin resistance and in vitro
activity of oxaciJIin, c1oramphenicol, erytromicine, ofloxacine and tri-
methoprim/sulphamethoxazole in Streptococcus pneumoniae (S. pn.) isolates.
Methods: Bacterial isolates of S. pn. were obtained from haemocultures,
sputum, ocular, throat and nasal swab in 70 HIV infected patients hospita-
lized in our clinic during 1998-1999. Susceptibility to test agents was assessed
by disk diffusion and E-test. Data on age, sex, group CDC classification,
CD4 counts and clinical outcome were recorded.
Results: There were 8 adults and 62 children, mean age 16 years (range 7-59
years) CDC class B (n = 40), and C (n = 30). Mean CD4 count was 289
lymphocites/mm3 There were 45 low respiratory tract infections (LRTI), 4
conjuctivitis, 9 tonsillitis, 12 pharingeal and nasal carriers. S. pn. isolates had
resistance to penicillin in 53.33% of cases and low resistant to some of the
other tested antibiotics. Serotypes 19 was isolated in 50% ofbacteraemia and
throat swab. Recurrent episodes ofpneumonia were observed in 12 patients.
Outcome of infectious episode was favorable 68/70 cases after antibiotic
therapy (2 adults expired)
Conclusions: Infections due to S. Pn. is frequent esspecialy in children and is
more severe in adults HIV infected. The frequency ofLRTI in these patients
suggests that anti-So pn. vaccination should be evaluated further.
[MoP27! Enterococws spp disease during HIV infection:
Frequency, risk factors, clinical features, antimicrobial
susceptibility and outcome
R. Manfredi, A. Nanetti, M. Ferri, F. Chiodo
Dept. ofClin. & Experim. Medicine, University ofB%gna, B%gna, Ita/y
Objective: To evaluate the role of Enterococcus spp as agents of bacterial
complications during HIV infection.
Methods: A survey of clinical charts of 2123 consecutive HIV-infected
patients (p) followed since 1991 was carried out, to identify all documented
episodes of Enterococcus spp disease, and to assess them according to some
epidemiological, clinical, and laboratory parameters. isolated positive cul-
tures from indwelling urinary catheters were ruled out.
Results: 143 episodes of enterococcal infection were detected in 117 p
(5.5%), aged 2-62 years. Genitourinary tract involvement accounted for
109 cases (76.2%), sepsis for 29, pneumonia and subcutaneous or lymph node
abscess for 2 cases each, and otitis for one case. From an etiological point of
view, E. faecalis was isolated in 126 cases, E. Jaecium in 7, and group D
streptococci in 10 cases; 66 episodes of 143 (46.2%) were polymicrobial in
origin (with E. coli as the most frequent associated pathogen). An increased
risk of developing enterococcal complications was seen according to the
progression of HIV disease (stage C vs stage A-B) (p < .01), immunode-
ficiency (CD4 + count < vs > 100 cells/ilL) (p < .(02), hospitalization
since ~3 days (p < .03), altered mentation or neurogenic bladder (p < .03),
urinary catheterization (p < .02), and prior use of broad-spectrum anti-
biotics or cotrimoxazole (p < .05). Hematogenous dissemination was
significantly associated with a diagnosis of AIDS, a CD4+ count < 40
cellS/ilL, and a neutrophil count < 1000 cellS/ilL (p < .001 to P < .05). No
significant difference was found in the frequency, localization, and severity
ofEII/erococcus spp infection, according to p's age, gender, and risk for HIV
infection. Bacterial isolates showed favorable susceptibility to penicillin
(95.1 % of strains), ampicillin and piperacillin (> 98%), and glycopeptides
(100%), while only clindamycin, chloramphenicol and erythromycin had a
resistance rate> 30% (> 80% for tetracycline). An adequate antimicrobial
therapy (mosdy carried out with semisynthetic penicillins), led to clinical
and microbiological cure in the large majority ofepisodes in 5-18 days, but
19 p (16.2%) had ~1 disease relapses, and in 5 P E. faecalis sepsis was a
contributing cause to death.
Discussion: The incidence and clinical role of HIV-related Enterococcus spp
infection are still poorly defined. Our experience shows that HIV-associated
EII/erococcus spp disease may be responsible for appreciable morbidity and
mortality. not previously recognized to the same extent. An advanced
underlying disease, deeply impaired immune defences, hospitalization,
instrumentation. and prior use of antimicrobials may act as supponing
factors, while a very low CD4 + count and neutropenia. may prompt a life-
threatening sepsis.
IMoP2S1 Emerging gram-negative organisms in the
immunocompromlsed host AcinetobiJcter spp and HIV infection
R. Manfredi, A. Nanetti, R. Valentini, F. Chiodo
Dept. ofClin. & Experim. Medicine, University ofBologna, Bologna, Italy
Objective: To evaluate the role of Acinetobacter spp in the setting of HIV
disease.
Methods: Clinical records of 2123 consecutive HIV-infected patients (p)
hospitalized in a 9-year period were reviewed, to identify all cases of
Acinetobacter spp disease, and to assess theit occurrence and outcome
according to their epidemiological, clinical, and therapeutic features.
Results: Ten p of2123 (0.47%) (6 males and 4 females, aged 32-39 years).
developed Acinetobaeter spp sepsis (4 p), urinary tract infection (3), pneumo-
nia (2), and septicemic pneumonia (1 p). A. calcoaceticus (4 isolates), A.lwoffii
(3) and Acinetobaeter spp (3), were cultured; in 4 p, other bacterial pathogens
were concurrently isolated. The mean CD4 + count was 122 ± 34 cells/pL,
and 6 P had a prior diagnosis of AIDS. Compared with other localizations,
sepsis was related to a significantly lower CD4+ count (p < .(01), and a
more frequent occurrence of neutropenia (p < .004). Hospital-acquired
disease (8 cases) prevailed over community-acquired one, involved more
frequendy p with AIDS and leukopenia, and led preferably to bacteremia (p
< .02); however, most episodes were not related to the use ofi.v. catheters,
mechanical ventilation, or other instrumentation. Antimicrobial, steroid,
and cotrimoxazole therapy were frequently carried out during the month
preceding disease onset, but no significant correlation was found between
the occurrence ofAcinetobacter ,pp disease and either p', age, gender, or type
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[MoP30IA case-control study of the spectrum of AIDS-
defining diseases before and after the highly active
antiretroviral therapy (HAARl} era
R. Manfredi, F. Chiodo
Department of Infectious Diseases, University if"Bologna, Bologna, Italy
Discussion: B. cata"halis is an emerging Gram-negative organism, com-
monly involved in upper and lower respiratory tract disease, although sepsis
and focal localizations have been increasingly observed in the immunocom-
promised host. Only 8 anecdotal episodes of HIV-associated B. catarrhalis
disease have been reported to date: 7 cases of community-acquired pneu-
monia were briefly quoted in large p series, while one episodes of sepsis
occurred in an infant (Wong VK, Scand J Infect Dis 1988; 20: 559). Our
experience shows that B. catarrhalis may be responsible for appreciable
morbidity in p with advanced HIV infection, especially when a low CD4
cell count or underlying respiratory diseases are of concern. Clinicians and
bacteriologists who care for HIV-infected p should carefully consider the
potential pathogenic role of Branhamella spp organisms, and their unpre-
dictable sensitivity profile (although a surprisingly favorable susceptibility
pattern was shown in our series).
of risk. Antibiotic susceptibility studies proved complete resistance to
ampicillin and cephalotin, and poor sensitivity to second-generation cepha-
losporins and gentamicin (1-4 isolates), while better susceptibility was
shown to ceftazidime, netilmicin and amikacin (6-8 strains), followed by
piperacillin, cotrimoxazole and quinolones. An adequate 6-13-day anti-
biotic course led to clinical and microbiological cure in all p, in absence of
recurrences or mortality.
Discussion: Since only 23 episodes of HtV-associated AcinetoblUter spp
disease have been described to date in 11 different reports (9 cases of sepsis,
!l of pneumonia, 2 of urinary tract involvement, 1 of i.v. access device
infection, 1 of meningitis, and 2 with unspecified localization), our series is
the largest one dealing with HIV-related Acinetobacter spp infection. As to
our experience, Acinetobacter spp is responsible for appreciable morbidity
among HIV-infected p, especially when an advanced underlying disease, a
low CD4 + count, neutropenia, and hospitalization are present. Clinicians
who care for HIV disease should consider the potential pathogenic role of
Acinetobaeter spp even in absence of some presumed risk factors (i.e.
instrumentation). A timely diagnosis and an adequate treatment (selected
on the ground of sensitivity testing), can avoid relapses and mortality.
IMoP29! Branhamella catarrlJalis pneumonia and HIV disease
R. Manfredi, A. Nanetti, R. Valentini, F. Chiodo
Dept. ofClin. & Experim. Medicine, University if"Bologna. Bologna, Italy
Objective: To assess the role ofBranhamella (Moraxella) ratarrhalis complica-
tions in the setting of HIV disease, and to evaluate their occurrence and
outcome according to some epidemiological and clinical features.
Methods and: Results: Clinical records of 2123 consecutive HIV-infected
patients (p) hospitalized in a 9-year period were reviewed, identifying 4 cases
of community-acquired B. catarrhalis pneumonia (diagnosed through cul-
tures of induced sputum or trachebronchial aspirate. Three adult p had a
diagnosis ofAIDS and a deep immunodeficiency (with a CD4 count < 60
cellsJJLI), while the fourth case interested a child with vertical HIV disease. A
concurrent respiratory infection by either Sir. pneumoniae or Myc. tuberculosis
was recognized in 2 cases of4, and p did not receive a potent antiretroviral
regimen prior to disease onset. B. catarrhalis strains were susceptible to all
tested antimicrobial compounds (co-amoxyclav, ureidopenicillins, second-
and third-generation cephalosporins, aztreonam, penems, aminoglycosides,
macrolides, chloramphenicol, quinolones, and cotrimoxa2ole), save ampi-
cillin in 2 p, and an adequate antimicrobial therapy led to clinical and
microbiological cure in all described episodes.
AIDS-defining 97-99 85-95
diseases n = 75 n = 225
P. carin;; pneum. 22 56
Candida esoph. 16 31
Neurotoxopl.nm. 9 26
Kaposi sarcoma 7 22
Tubetculosis 6 5
Wasting syndr. 5 8
Non-Hodg. lymph. 3 7
HlV encephalop. 2 11
Cytomegaloviros. t 16
Cryptococcosis 1 8
Mycobacteriosis 0 7
Other diseases 3 28
Discussion: Among the relevant changes observed in the natural history of
HIV disease thanks to the recent availability ofHAART, the spectrum of
AIDS-associated diseases presented only minor modifications, compared
with that recognized before 1996. Several opportunistic disorders related to a
severe immunodeficiency are still relatively frequent. since the large major-
ity ofAIDS cases diagnosed in the HAART era occur in p with advanced but
previously missed (or not effectively treated) HIV infection. A strong clinical
suspicion for immunodeficiency-related opportunism should be maintained
when caring for p with recently identified or insufficiently treated HIV
infection.
Objective: To assess the spectrum of AIDs-defining illnesses ofpatients (p)
diagnosed during the HAART era, compared with that observed before
HAART introduction.
Methods: Defining diseases of 75 consecutive p with AIDS diagnosed in
1997-1999, were compared with those of225 p randomly selected from the
436 p identified from 1985 to 1995.
Results: An impressive reduction of AIDS diagnoses followed the intro-
duction of HAART: a mean number of24 cases per year was observed in
1997-1999, opposed to over 65 mean cases per year in 1991-1995 (p <
.001). When considering the single AIDs-defining diseases, a significant
drop ofCytomegalovirosis (p < .05), and a tendency towards a reduction of
cryptococcosis, mycobacteriosis and HIV encephalopathy was observed
during the last 3 years compared with the pre-HAART period, while a
significant increase of tuberculosis (p < .03) and a tendency to a rise of
pneumocystosis, Candida esophagitis, wasting syndrome and non-Hodgkin
lymphoma, was concurrently observed; neurotoxoplasmosis and Kaposi
sarcoma showed a substantially stable incidence. Since in the large majority
of recent cases HIV infection was identifed concurrently with an advanced
immunodeficiency and an AIDS-defining event, or anti-HIV treatment was
refused or carried out with poor adherence, only 7 p of 75 (9.3%) who
developed AIDS since 1997 received HAART prior to diagnosis. Further-
more, a limited increase ofmean CD4 + cell count was found in p diagnosed
during the HAART era, compared with the pre-HAART period (86.7 ±
108.3 vs 73.2 ± 101.9 cells/ItL).
R. Manfredi, A. Nanetti. R. Valentini, F. Chiodo
Dept. if"Clinical & Experim. Medicine, University ofBologna, Bologna, Italy
Objective: To assess clinical and microbiological features of Campylobacter
spp disease in HtV-infected patients (p).
Methods: A retrospective survey of clinical and bacteriological records of
2123 consecutive p hospitalized since 1991, was performed.
Results: 13 p (8 males and 5 females, aged 29-48 years; 5 i.v. drug users, 5
homosexuals, and 3 heterosexuals), had a documented Campylobacter spp
disease: enteric tract infection in 6 cases (characterized by abdominal pain,
nausea, fever, and weight loss), sepsis in 4, and bacteremic diarrhea in the
remaining 3 p. C. jejuni was identified in 12 cases, and C. fetus in the
remaining p. A severe immunodeficiency was present, as expressed by a
mean CD4 + count of62.5 ± 32.4 cells/JLL, and a mean neutrophil count of
1320 ± 366 cellsJJLL, while lOp of13 had a prior diagnosis ofAIDS. In only
2 p of 13 the infection wa. diagnoocd after "-7 day. ofh""pitalization. and
neither adjunctive risk factors nor exposure to possibly contaminated food
was recognized; 8 p were on continuative cotrimoxa2ole prophylaxis.
Bacterial isolates tested highly resistant to cephalotin (92.3% of strains),
but quite susceptible to cefotaxime, ceftriaxone, gentamicin, ciproftoxacin,
erythromycin and chloramphenicol (16.9 to 100%), and cotrimoxa2ole and
IMoP31 IEnteric and disseminated infection by campylobacter
spp organisms in patients with HIV disease
ceftazid. + netilmicin (II)
ceftriax. + netilmicin (7)
c1arithromycin (6)
co-amoxyclav (9)
respiratory ocutro- antimicrobial thenpy(days)
phil/CD4
countl"L co-infection
Myr. tub",. 7810158
3084/47
Srr. pM4m. 2315/568
9412/24
38
36
11
34
1994
1996
1997
1999
patient year
1.
2.
3.
4.
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tetracycline (53.8 to 69.2% of isolates). Second- or third-generation cepha-
losporins plus aminoglycosides, or isolated quinolones. macrolides, or
cephalosporins. proved clinically and microbiologically effective in 12 P
after 8-18 days of administration, but a relapse due to strains bearing the
same susceptibility profile occurred in 5 P after 2-8 weeks. Two p had a
lethal septic shock-like syndrome (occurred during a relapse in one case).
despite the administration of a seemingly adequate therapy.
Dlscu5sion: In HlV-infected p, enteric Gram-negative microaerophilic
organisms belonging to CampylobtUter spp (mostly C. jejuni, but also C.
fetus, C. coli, C. laridis and C. upsaliensis), have been recorded as agents of
prolonged and recurrent diarrhea, potentially severe sepsis. and occasionally
cholecystitis and osteomyelitis. Advanced immunodeficiency may promote
hematogenous spread, and a life-threatening course. Mostly community-
acquired in origin, HIV-related CampylobtUter spp disease often requires
multiple and prolonged antibiotic courses, possibly responsible for induced
antibiotic resistance. An increasing resistance to beta-Iactams, tetracyclines,
cotrimoxazole. and also quinolones has been detected worldwide, so that
treatment should be always guided by in vitro assays. Campylobaeter spp
disease should be carefully considered when facing a febrile HlV-infected p
with advanced immunodeficiency. even in absence ofobvious exposure and
intestinal involvement, due to the potentially relapsing and life-threatening
disease course, and the unpredictable antibiotic sensitivity of these patho-
gens.
IMoP32IOlnlcal and microbiological features of Enterobacter
spp complications In patients hospitalized for HIV disease
R. Manfredi. A. Nanetti. M. Ferri, F. Chiodo
Dept. ofClinical & Experim. Medicine, University ofBologna, Bologna, Italy
Objective: To assess the role of Enterobacter spp as agents of HIV-associated
bacterial complications.
Methods: Clinical and microbiological records ofall HlV-infected patients
(p) hospitalized since 1990 were retrospectively reviewed. to identify all
documented cases of EnterobtUter spp infection.
Results: 13 paged 23-57 years. developed 7 cases ofurinary tract infection.
4 of sepsis. and 2 of pneumonia. E. aerogenes was isolated in 5 cases. and E.
cloacae and Enterobaeter spp in 4 cases each. A severe immunodeficiency
characterized all episodes: our p had a mean CD4 count of58.5 ± 27.8 cellsf
J.l.L (31.1 ± 17.3 cells/J.l.L for p with bacteremia) (p < .05). while a
neutrophil count < 1000 cells/J.l.L was present in 7 cases of 13 (including
all 4 septic p) (p < .05); 8 P had a previous diagnosis ofAIDS. EnterobtUterspp
infections had a nosocomial origin (since occurred after "2:.72 hours of
admission) in 8 cases of 13 (including all cases ofsepsis), but central catheters
were present in only 2 cases, and no p underwent surgery, mechanical
ventilation. or other instrumentation; 3 p with urinary tract infection
underwent prior bladder catheterization. During the month preceding
disease onset. 5 and 3 p of 13 were treated with broad-spectrum antibiotics
or steroids respectively, while cotrimoxazole was administered to 8 p. In
vitro antibiotic susceptibility assays showed an elevated resistance to ampi-
cillin and cephalotin (92.3% ofisolates), while 53.8 to 84.6% ofstrains tested
sensitive to piperacillin, cefotaxime, ceftriaxone, gentamicin. amikacin.
netilmicin. ciproftoxacin and cotrimoxazole; 2 E. cloacae strains proved
multiresistant. but remained sensitive to carbapenems. A 5-13-day course
ofantimicrobial therapy (third-generation cephalosporins or ureidopenicil-
lins plus aminoglycosides in 11 P of 13). led to a complete clinical and
microbiological cure, in absence of related mortality or disease relapses.
Discussion: EnlerobtUrer spp organisms are ornithine-positive motile gram-
negative bacilli ofenvironmental origin, increasingly responsible for bacter-
ial complications in p with underlying diseases, especially when hospitaliza-
tion or instrumentation are of concern. However. only 6 episodes of HIV-
related Enterobacter spp disease were reported to date: 3 cases ofsepsis. and one
case each ofurinary tract infection, pneumonia, and vertebral osteomyelitis.
Our experience therefore presents the largest series of HIV-associated
Enterobacter spp disease. A relationship with advanced HlV disease, a low
CD4 count. neutropenia. hospitalization. and prior use of antibiotics was
demonstrated, while instrumentation seemed to playa minor role; hema-
togenous dissemination involved the most compromised p. Bacterial isolates
showed a more favorable susceptibility profile than expected: all p were
successfully cured. without any notable consequence on HIV disease course.
IMoP33I Demographic. epidemiological. and therapeutic
features of AIDS cases disclosed during the HAART era: A case-
control study
R. Manfredi. F. Chiodo
Department of Infectious Diseases, University ofBologna, Bologna, Italy
Objective: To compare some demographic, epidemiological, and therapeu-
tic characteristics of patients (p) who developed AIDS during the HAART
cra, with those observed before HAART introduction (occurred in 1996).
Plltlents and Methods: During the past 15 years, a substantially stable
number of ~1000 known HIV-infected p referred to our outpatient
centre, and 599 diagnoses of AIDS were made. Selected features of 75
consecutive p with diagnosis of AIDS made from 1997 to 1999, were
compared with those of 225 p randomly selected from the 436 p notified
from 1985 to 1995, in a case-control study.
Results: The number of newly detected cases of AIDS had a sharp drop in
frequency shortly after the introduction of HAART, with 38, 21 and 15
cases diagnosed in 1997. 1998 and 1999 respectively. vs over 80 cases per year,
in 1991 to 1995 (p < .001). Compared with the pre-HAART era, during the
last 3 years a tendency towards an incrcased involvement of the female
gender (34.7% vs 26.7%), and a slight increase of mean CD4+ count at
diagnosis (86.7 ± IOS.3 vs 73.2 ± 101.9 cells/J.l.L) were found, while a
significant rise of mean p's age (39.8 ± 8.2 vs 34.2 ± 7.3 years; p < .001).
and a proportional increase ofheterosexuals (27 vs 37; P < .001) vs i.v. drug
users (34 vs 134; p < .04). were pointed out. However, only 7 p of75 who
developed AIDS since 1997 (9.3%) received HAART prior to diagnosis,
since HIV infection was disclosed concurrently with an AIDS-defining
illness in 46 p who were not aware of it, or HAART was refused or taken
with poor compliance in the remaining 22 p.
Discussion: Although the introduction of HAART significanly changed
the natural history of HIV disease. less appreciable modifications can be
found in the features ofnewly diagnosed cases ofAIDS. In fact, the increased
incidence among women. the higher mean p's age at diagnosis. and the
greater role ofheterosexual transmission, are likely to depend on progressive
modifications occurred in the epidemiology of the HlV pandemic. On the
other hand, the great majority (> 90%) of AIDS cases detected in the
HAART era actually regard p with an advanced but previously unrecog-
nized (or untreated) HIV infection, who are still at risk of opportunistic
diseases related to a deep immunodeficiency, so that the availability of
HAART does not seem to act significandy on several demographic and
epidemiological features ofnewly identified AIDS.
IMOP34! Eects of the Introduction of highly active
antlretroviral therapy (HAART) on the frequency and features of
HIV-related bacteremia
R. Manfredi, F. Chiodo
Department of Inftctious Diseases, University ofBologna, Bologna, Italy
Objective: To evaluate the frequency. etiological spectrum, risk factors and
outcome ofHIV-related bacteremia since the introduction ofHAART.
Methods: The disease features of all episodes of sepsis occurred in HIV-
infected patients (p) hospitalized during the years 1994-1995 (pre-HAART
period) were compared with those observed during the HAART era (1997-
1999).
Results: 360 overall p suffered from sepsis in the considered periods, but the
disease frequency was significantly lower during 1997-1999 vs 1994-1995
(6.2 vs 16.5 episodes per 100 p-years: p < .0001). No significant difference
was shown according to p's age, gender. and risk for HlV infection, but an
advanced (stage C) HIV disease was significantly less frequent among p who
had sepsis during HAART vs pre-HAART era (p < .002). and concurrent
use of antiretrovirals became significandy more common during recent
years (p < .0001), together with an increased incidence of gram-negative
oxydase-positive etiology (i.e. Pseudomonas spp and non-fermenting organ-
isms) (p < .05). Among potential risk factors. a greater CD4+ count (p <
.0001). and a reduced rate of neutropenia (p < .02), were found during the
HAART era. together with a significant increase of nosocomially- vs
community-acquired infections (p < .002), despite a significant drop of
mean duration of admission (p < .0001). On the other hand, no significant
difference was found as to use of i.v. catheters, prior administration of
cotrimoxazole, antibiotics and steroids, and disease outcome (11 cases of
related death found in the pre-HAART period. vs 3 in the HAART era).
Discussion: A sharp drop in the incidence of AIDS-related morbidity and
mortality followed the introduction ofHAART. but only limited literature
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data are available about the frequency and clinical features of sepsis in the
HAART era. The dramatical 25-fold decrease in frequency of HIV-related
bacteremia observed during the HAART era compared with preceding
years is associated with a less advanced HIV disease and immunodeficiency
and a reduced duration of related hospitalization, while an increased rate of
nosocomially-acquired pathogens was seen. The changing epidemiological,
microbiological, and clinical features ofHIV-related sepsis may significantly
influence the future management srrategies of HIV infection.
hiperferritinemic trend associated to increased hemosiderin were only on
40% cases:
Disease features
n. p suffering from sepsi....bacteremia
n. disease episodes per 100 p-years
n. p in disease stage A + H/C
n. p receiving non-HAART/HAART regimen
Mean CD4+ lymphocyte count/ilL ± SD
n. p with neutrophil count < 1000/IlL
n. community-acquired/nosocomial origin
211
16.5
56/155
118/0
75 ± 43
62
123/88
1997-99
149
6.2
64/85
38/89
97 ± 49
27
62/87
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IMoP3SIIntracelluiar cytokines as early predictors of response
to highly active antiretroviral therapy (HAART)
E. Lew!, L. Gallagher2, M. Kuehnert!, D. Rimland2, S. Phillips!, M.
Hubbard', W. jarvis! , J. jason1
'Centersfor Disease Control and Prevention; 2Veterans Affairs Medical Center,
Atlanta, Georgia, United States
ObjectIve: To assess initial and early immune responses to HAART.
Methods: Peripheral blood mononuclear cells (PBMCs) from 12 HIV-l
infected patients were incubated with brefeldin-A and with or without
phorbol12-myristate l3-aeetate (PMA) and ionomycin. PBMCs were then
assessed for numerous surface antigens, memory/activation markers, and
intracellular cytokines, using four color cytoftuorometric analyses. Patients
were evaluated at pre-treatment and at 1, 2. and 3 weeks post-initiation of
HAART. Univariate analyses were done using Kruskal-Wallis tests.
Results: Six patienrs remained on therapy and returned for full follow-up.
All had a ~2-log decline in viral titers and/or decline to undetectable levels.
There were no significant changes in the median percentages and numbers of
CD4 + or CD8 + T-cells pre-therapy to week 3 (for CD4 + T-cells: 8.3%
to 8.8%, 138 to 138; for CD8+ T-cells: 27.2% to 24.0%, 436 to 371).
However, there were significant declines in the percentages ofCD4+ and
CD8+ lymphocytes spontaneously producing TNF-a (for CD4+ lym-
phocytes: 2.4% to 0.5%, p = 0.025; for CD8 + lymphocytes: 0.6% to
0.2%, p = 0.037). The percentage ofCD3+ T-cells spontaneously produ-
cing IL-4 also declined (1.8% to 0.8%, P = 0.004).
Conclusion: Spontaneous production ofTNF-a, a pro-inflammatory type I
cytokine, and of IL-4, a type II cytokine, decreased significantly within 3
weeks of successful HAART. None of the other immune parameters
assessed, including the percentages and numbers of CD4 + and CD8 + T-
cells and the percentage ofCD45RO + cells changed significantly. Changes
in the percentages of CD4 + and CD8 + lymphocytes spontaneously
producing TNF-a and of CD3 + T-cells spontaneously producing IL-4
may be early indicators of successful HAART.
IMOP36! serum ferritin levels as prognostic factor in AIDS
patients
Y. Franco!, M. Molina', A.J. Rodriguez3, M. Bermudez2
IMedidne Ill, Vargas Hospital ofCaracas; 2Pharmacology Laboratory; JVargas
Medical School, Caracas, Venezuela
objectives: Study the inverse relation between ferritin and CD4 lumpho-
cytes count to use it as prognostic marker in AIDS patients.
Methods: We included 40 patients with AIDS/HIV infection diagnosis. We
Studied serum ferritin levels and CD4 cells count, hematology and blood
chemistry. Ferritin levels were linked with Cf)4 eclb count, and with other
variables. Statistical analysis was at 95% confidence.
Results: Average measuremenrs were: CD4115.75/mm3, ferritin 322.62 ng/
mI, albumin 2.89 g/dl, ESR 71.07 seg. Inverse relation Ferritin/CD4 was at p
> 0.05 and Ferritin/Albumin was at p = 0.036 (OR 0.249). 22 patients
(55%) were hiperferritinemic (18 patients of these were AIDS C3). An
Condusions: Most patients presented hiperferritinemia, non explainable
due to different factors. Its direct relation to ESR and inverse to albumin
suggests its behavior as acute-phase reactant. therefore, serum ferritin levels
may be useful as direct and unspecific marker of opportunistic infections in
AIDS patienrs.
IMoP371 Evaluation of the Vldas HIV duo test In two
independent routine laboratories
W. Fierz1, M. jutzi2, P. Vernazzal, P. Erb2
IInstitute for Clinical Microbiology and Immunology, St. Gallen; 2Institute for
Medical Microbiology, University ofBasel Basel, Switzerland
Objective: To compare the Vidas HIV Duo with HIV 3. generation- and
p24-assays in two independent routine laboratories.
Methods: In St. GalIen, 4400 clinical samples were tested in parallel with the
Vidas HIV Duo (bioMerieux SA) and Cobas Core Anti-HIV-lfHIV-2 EIA
DAGS (F. Hoffmann-La Roche). In addition, 970 samples were tested for
p24 antigen with the HIVAG-l Monoclonal (Abbott). In Basel, 3007 sera
were compared with Vidas HIV Duo and AxSym HIV-l/HIV2 (Abbott). In
both laborarories, discrepant results were resolved with p24-antigen assays.
Western Blors, and evaluation of consecutive sera.
Results: In St. Gallen, from 4400 samples 31 (0.7%) were true positiv (TP)
and 16 (0.37%) falsch positiv (FP) in the Vidas HIV Duo, yielding a specifity
of 99.63%. In comparison, the specificity of the p24-antigen assay was
98.65% (13 FP (1.34%) samples). Seven primary HIVinfection were
detected as identified by a positive Vidas HIV Duo, a positive p24 antigen
assay and by clinical criteria. Four samples were negative in the AxSym and 5
in the Cobas Core. In Basel, from 3007 samples 36 (1.2%) were TP and 11
(0.37%) were FP in the Vidas Duo, yielding a specificity of 99.57%. In
comparison, the specificity ofthe AxSym was 99.9% (3 FP (0.1 %) samples).
Seven primary HIV-infection were identified, 4 samples were negative in
the AxSym.
Conclusions: The Vidas HIV Duo yielded in two independent laboratories
almost identical results. Although having a somewhat lower specificity
compared to the 3. generation assays tested, its strength and superiority lies in
the identification of primary HIV-infections. Moreover, for secreening of
primary HIV-infections the Vidas HIV Duo is superior to the Abbott p24-
assay.
IMoP3S! Multicenter evaluation of HIV DUO (bioM8rieux): An
assay for simultaneous detection of HIV antibodies and p24
antigen
P. Portincasal , R. Grill02, P. Pauri3 , M. G. Colao·, P. P. Valcavi', D.
Speziale2, G. Mazzarelli·, E. De Majo·, P. E. Varald03, G. Fadda2, C.
Chezzi', G. Deltori'
'Istituti di Microbiologia Universira di Parma; 2Universittl Cattolica del Sacro
Cuore di Roma; JUniversita di Ancona; ·Servizio ImmunosieroloJlia
Microbiologica Azienda Ospedaliera Careggi di rirenze, Italy
Objectives: To evaluate the performances ofa new HIV fourth generation
screening assay in a multicenter survey.
Methods: Second or third generation assaies and western blotting were used
to test sera belonging to hospitalized patients, blood donnors as well as
